Galapagos excels during great year for the Brussels stock exchange

02/01/2016

During this past year Galapagos truly excelled on the Brussels stock exchange. The share of the biotechnology company rose by no less than 271 percent in 2015.

The strong test results of filgotinib against rheumatoid arthritis underpinned this success. Supported by this, CEO Onno van de Stolpe succeeded in entering into a partnership with pharmaceutical giant Gilead Sciences and to successfully enter NASDAQ.

Galapagos was founded in 1999 in Mechelen as a biotechnology company in the clinical phase, specializing in the discovery and development of medicines with new modes of action. The current Galapagos Group, including its subsidiary Fidelta, has some 400 employees in its head office in Mechelen and offices in the Netherlands, France and Croatia.

2015 was also an excellent year for the entire Brussels stock exchange. Most analysts agree that the incentive policy of the European Central Bank was certainly a factor in this success. The listing of the basket of Bel20 shares increased for the fourth year in a row, with 15.7 percent in 2015.